3-(2-amino-ethyl)-alkylidene)-thiazolidine-2,4-dione and 1-(2-amino-ethyl)-alkylidene-1,3-dihydro-indol-2-one derivatives as selective sphingosine kinase 2 inhibitors

Abstract

3-(2-amino-ethyl)-5-[3-(4-substituted-phenyl)-alkylidene)-thiazolidine-2,4-dione and 1-(2-amino-ethyl)-3-alkylidene-1,3-dihydro-indol-2-one and derivatives thereof are provided for use as selective SphK2 inhibitors and for use in the treatment of human diseases, such as cancer.

We claim: 
     
         1 . A compound of Formula I: 
       
         
           
           
               
               
           
         
       
       wherein,
 R 1  is selected from the group consisting of: C 3 -C 14  alkyl and C 3 -C 14  alkoxyl; 
 R 2 , R 3 , R 4  and R 5  may be the same or different and are independently selected from: H, C 1 -C 8  alkyl, C 1 -C 8  alkoxyl, C 1 -C 8  alkylcarbonyl, halogen, hydroxyl, amino, nitro, and cyano; 
 V is S, O, NH, or CH 2 ; 
 X is C 1 -C 4  alkyl; 
 Y is C 1 -C 4  alkyl; 
 Z is S or O or NR 6  in which R 6  is selected from the group consisting of: H, C 1 -C 8  alkyl, or isopropyl, tert-butyl, a saturated or unsaturated monocyclic ring with ring size ranging from 3-7 carbons per ring, and phenyl which may be substituted with one or more substituents selected from the group consisting of: C 1 -C 8  alkyl, C 1 -C 8  alkoxyl, C 1 -C 8  alkylcarbonyl, halogen, hydroxyl, amino, nitro, and cyano; and 
 W is NR 7 R 8  where R 7  and R 8  may be the same or different and are independently selected from H; C 1 -C 4  alkyl; a saturated heterocycle comprising N bonded directly to Y; and an unsubstituted or substituted guanidine moiety. 
 
     
     
         2 . The compound of  claim 1 , wherein the number of carbon atoms in said saturated or unsaturated monocyclic ring with ring size from 3-7 is selected from the group consisting of 3, 4, 5, 6, and 7. 
     
     
         3 . The compound of  claim 1 , wherein said saturated heterocycle is selected from the group consisting of morpholine, piperidine, piperazine, and pyrrolidine. 
     
     
         4 . The compound of  claim 1 , wherein said compound is selected from 3-(2-aminoethyl)-5-[3-(4-butoxyl-phenyl)-propylidene]-thiazolidine-2,4-dione and 3-(2-aminoethyl)-5-[3-(4-octyl-phenyl)-propylidene]-thiazolidine-2,4-dione. 
     
     
         5 . A compound of Formula II: 
       
         
           
           
               
               
           
         
       
       wherein,
 R 10  is selected from the group consisting of: C 3 -C 14  alkyl, C 3 -C 14  alkoxyl; 
 R 11 , R 12 , R 13  and R 14  may be the same or different and are independently selected from: H, C 1 -C 8  alkyl, C 1 -C 8  alkoxyl, C 1 -C 8  alkylcarbonyl, halogen, hydroxyl, amino, nitro, and cyano; 
 R 15 , R 16 , R 17  and R 18  may be the same or different and are independently selected from the group consisting of: C 1 -C 8  alkyl, C 1 -C 8  alkoxyl, C 1 -C 8  alkylcarbonyl, halogen, hydroxyl, amino, nitro, and cyano; 
 X is C 1 -C 4  alkyl; 
 Y is C 1 -C 4  alkyl; 
 and 
 W is NR 19 R 20  where R 19  and R 20  may be the same or different and are selected from the group consisting of: H, C 1 -C 4  alkyl; a saturated heterocycle comprising N bonded directly to Y, and an unsubstituted or substituted guanidine moiety. 
 
     
     
         6 . The compound of  claim 5 , wherein the number of carbon atoms in said saturated or unsaturated monocyclic ring with ring size from 3-7 is selected from the group consisting of 3, 4, 5, 6, and 7. 
     
     
         7 . The compound of  claim 5 , wherein said saturated heterocycle is selected from the group consisting of morpholine, piperidine, piperazine, and pyrrolidine. 
     
     
         8 . A method of treating diseases or conditions associated with positive SphK2 activity in a patient in need thereof, comprising the step of administering to said patient a sufficient quantity of at least one compound of Formula I or Formula II: 
       
         
           
           
               
               
           
         
       
       wherein, 
       in Formula I: 
       R 1  is selected from the group consisting of: C 3 -C 14  alkyl and C 3 -C 14  alkoxyl;
 R 2 , R 3 , R 4  and R 5  may be the same or different and are independently selected from: H, C 1 -C 8  alkyl, C 1 -C 8  alkoxyl, C 1 -C 8  alkylcarbonyl, halogen, hydroxyl, amino, nitro, and cyano; 
 V is S, O, NH, or CH 2 ; 
 X is C 1 -C 4  alkyl; 
 Y is C 1 -C 4  alkyl; 
 Z is S or O or NR 6  in which R 6  is selected from the group consisting of: H, C 1 -C 8  alkyl, or isopropyl, tert-butyl, a saturated or unsaturated monocyclic ring with ring size ranging from 3-7 carbons per ring, and phenyl which may be substituted with one or more substituents selected from the group consisting of: C 1 -C 8  alkyl, C 1 -C 8  alkoxyl, C 1 -C 8  alkylcarbonyl, halogen, hydroxyl, amino, nitro, and cyano; and 
 W is NR 7 R 8  where R 7  and R 8  may be the same or different and are independently selected from H; C 1 -C 4  alkyl; a saturated heterocycle comprising N bonded directly to Y; and an unsubstituted or substituted guanidine moiety; 
 and wherein 
 
       in Formula II:
 R 10  is selected from the group consisting of: C 3 -C 14  alkyl, C 3 -C 14  alkoxyl; 
 R 11 , R 12 , R 13  and R 14  may be the same or different and are independently selected from: H, C 1 -C 8  alkyl, C 1 -C 8  alkoxyl, C 1 -C 8  alkylcarbonyl, halogen, hydroxyl, amino, nitro, and cyano; 
 R 15 , R 16 , R 17  and R 18  may be the same or different and are independently selected from the group consisting of: C 1 -C 8  alkyl, C 1 -C 8  alkoxyl, C 1 -C 8  alkylcarbonyl, halogen, hydroxyl, amino, nitro, and cyano; 
 X is C 1 -C 4  alkyl; 
 Y is C 1 -C 4  alkyl; 
 
       and
 W is NR 19 R 20  where R 19  and R 20  may be the same or different and are selected from the group consisting of: H, C 1 -C 4  alkyl; a saturated heterocycle comprising N bonded directly to Y, and an unsubstituted or substituted guanidine moiety. 
 
     
     
         9 . The method of  claim 8 , wherein the number of carbon atoms in said saturated or unsaturated monocyclic ring with ring size from 3-7 is selected from the group consisting of 3, 4, 5, 6, and 7. 
     
     
         10 . The method of  claim 8 , wherein said saturated heterocycle is selected from the group consisting of morpholine, piperidine, piperazine, and pyrrolidine. 
     
     
         11 . The compound of  claim 8 , wherein said compound is selected from 3-(2-aminoethyl)-5-[3-(4-butoxyl-phenyl)-propylidene]-thiazolidine-2,4-dione and 3-(2-aminoethyl)-5-[3-(4-octyl-phenyl)-propylidene]-thiazolidine-2,4-dione. 
     
     
         12 . The method of  claim 8 , wherein said disease or condition associated with positive SphK2 activity is selected from the group consisting of: cancer, arthrosclerosis, arthritis, diabetes, obesity, osteoporosis, inflammatory diseases and Alzheimer's disease. 
     
     
         13 . A method of inhibiting SphK2, comprising the step of exposing said SphK2 to at least one compound of Formula I or Formula II: 
       
         
           
           
               
               
           
         
       
       wherein, 
       in Formula I: 
       R 1  is selected from the group consisting of: C 3 -C 14  alkyl and C 3 -C 14  alkoxyl;
 R 2 , R 3 , R 4  and R 5  may be the same or different and are independently selected from: H, C 1 -C 8  alkyl, C 1 -C 8  alkoxyl, C 1 -C 8  alkylcarbonyl, halogen, hydroxyl, amino, nitro, and cyano; 
 V is S, O, NH, or CH 2 ; 
 X is C 1 -C 4  alkyl; 
 Y is C 1 -C 4  alkyl; 
 Z is S or O or NR 6  in which R 6  is selected from the group consisting of: H, C 1 -C 8  alkyl, or isopropyl, tert-butyl, a saturated or unsaturated monocyclic ring with ring size ranging from 3-7 carbons per ring, and phenyl which may be substituted with one or more substituents selected from the group consisting of: C 1 -C 8  alkyl, C 1 -C 8  alkoxyl, C 1 -C 8  alkylcarbonyl, halogen, hydroxyl, amino, nitro, and cyano; 
 
       and
 W is NR 7 R 8  where R 7  and R 8  may be the same or different and are independently selected from H; C 1 -C 4  alkyl; a saturated heterocycle comprising N bonded directly to Y; and an unsubstituted or substituted guanidine moiety; 
 and wherein 
 
       in Formula II:
 R 10  is selected from the group consisting of: C 3 -C 14  alkyl, C 3 -C 14  alkoxyl; 
 R 11 , R 12 , R 13  and R 14  may be the same or different and are independently selected from: H, C 1 -C 8  alkyl, C 1 -C 8  alkoxyl, C 1 -C 8  alkylcarbonyl, halogen, hydroxyl, amino, nitro, and cyano; 
 R 15 , R 16 , R 17  and R 18  may be the same or different and are independently selected from the group consisting of: C 1 -C 8  alkyl, C 1 -C 8  alkoxyl, C 1 -C 8  alkylcarbonyl, halogen, hydroxyl, amino, nitro, and cyano; 
 X is C 1 -C 4  alkyl; 
 Y is C 1 -C 4  alkyl; 
 
       and
 W is NR 19 R 20  where R 19  and R 20  may be the same or different and are selected from the group consisting of: H, C 1 -C 4  alkyl; a saturated heterocycle comprising N bonded directly to Y, and an unsubstituted or substituted guanidine moiety. 
 
     
     
         14 . The method of  claim 13 , wherein the number of carbon atoms in said saturated or unsaturated monocyclic ring with ring size from 3-7 is selected from the group consisting of 3, 4, 5, 6, and 7. 
     
     
         15 . The method of  claim 13 , wherein said saturated heterocycle is selected from the group consisting of morpholine, piperidine, piperazine, and pyrrolidine. 
     
     
         16 . The compound of  claim 13 , wherein said compound is selected from 3-(2-aminoethyl)-5-[3-(4-butoxyl-phenyl)-propylidene]-thiazolidine-2,4-dione and 3-(2-aminoethyl)-5-[3-(4-octyl-phenyl)-propylidene]-thiazolidine-2,4-dione. 
     
     
         17 . The method of  claim 13 , wherein said SphK2 is present in a cell. 
     
     
         18 . The method of  claim 17 , wherein said cell is selected but not limited to a cancer cell, cardiocyte cell, epithelial cell, pancreatic cell, and neuronal cell, and said method includes a step of exposing said cell to said at least one compound of Formula I or Formula II. 
     
     
         19 . A method of inhibiting growth or killing or damaging cancer cells, comprising the step of exposing said cancer cells to a compound of Formula I or Formula II: 
       
         
           
           
               
               
           
         
       
       wherein, 
       in Formula I: 
       R 1  is selected from the group consisting of: C 3 -C 14  alkyl and C 3 -C 14  alkoxyl;
 R 2 , R 3 , R 4  and R 5  may be the same or different and are independently selected from: H, C 1 -C 8  alkyl, C 1 -C 8  alkoxyl, C 1 -C 8  alkylcarbonyl, halogen, hydroxyl, amino, nitro, and cyano; 
 V is S, O, NH, or CH 2 ; 
 X is C 1 -C 4  alkyl; 
 Y is C 1 -C 4  alkyl; 
 Z is S or O or NR 6  in which R 6  is selected from the group consisting of: H, C 1 -C 8  alkyl, or isopropyl, tert-butyl, a saturated or unsaturated monocyclic ring with ring size ranging from 3-7 carbons per ring, and phenyl which may be substituted with one or more substituents selected from the group consisting of: C 1 -C 8  alkyl, C 1 -C 8  alkoxyl, C 1 -C 8  alkylcarbonyl, halogen, hydroxyl, amino, nitro, and cyano; and 
 W is NR 7 R 8  where R 7  and R 8  may be the same or different and are independently selected from H; C 1 -C 4  alkyl; a saturated heterocycle comprising N bonded directly to Y; and an unsubstituted or substituted guanidine moiety; 
 and wherein 
 
       in Formula II:
 R 10  is selected from the group consisting of: C 3 -C 14  alkyl, C 3 -C 14  alkoxyl; 
 R 11 , R 12 , R 13  and R 14  may be the same or different and are independently selected from: H, C 1 -C 8  alkyl, C 1 -C 8  alkoxyl, C 1 -C 8  alkylcarbonyl, halogen, hydroxyl, amino, nitro, and cyano; 
 R 15 , R 16 , R 17  and R 18  may be the same or different and are independently selected from the group consisting of: C 1 -C 8  alkyl, C 1 -C 8  alkoxyl, C 1 -C 8  alkylcarbonyl, halogen, hydroxyl, amino, nitro, and cyano; 
 X is C 1 -C 4  alkyl; 
 Y is C 1 -C 4  alkyl; 
 
       and
 W is NR 19 R 20  where R 19  and R 20  may be the same or different and are selected from the group consisting of: H, C 1 -C 4  alkyl; a saturated heterocycle comprising N bonded directly to Y, and an unsubstituted or substituted guanidine moiety. 
 
     
     
         20 . The method of  claim 19 , wherein the number of carbon atoms in said saturated or unsaturated monocyclic ring with ring size from 3-7 is selected from the group consisting of 3, 4, 5, 6, and 7. 
     
     
         21 . The method of  claim 19 , wherein said saturated heterocycle is selected from the group consisting of morpholine, piperidine, piperazine, and pyrrolidine. 
     
     
         22 . The compound of  claim 19 , wherein said compound is selected from 3-(2-aminoethyl)-5-[3-(4-butoxyl-phenyl)-propylidene]-thiazolidine-2,4-dione and 3-(2-aminoethyl)-5-[3-(4-octyl-phenyl)-propylidene]-thiazolidine-2,4-dione. 
     
     
         23 . The method of  claim 19 , wherein said cancer cells are of a type selected from the group consisting of: leukemia, lymphoma, sarcoma, neuroblastoma, lung cancer, skin cancer, head squamous cell carcinoma, neck squamous cell carcinoma, prostate cancer, colon cancer, breast cancer, ovarian cancer, cervical cancer, brain cancer, bladder cancer, and pancreatic cancer.